ClinicalTrials.gg
CompletedNCT03009396MAPUS2Updated Feb 24, 2021Results posted

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

A Phase 3 interventional study of RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) in Crohn Disease, sponsored by RedHill Biopharma Limited. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by RedHill Biopharma Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Crohn Disease with a site in Poland — 34 open to participants now, 51 under way, 32 of them phase 3. Crohn Disease · Poland.

Enrollment
132nd of 152
54 · median 192
Started
2017
with 9 others
Phase 3
83 of 161
19 open now
Registered
63rd of 161
by date

Among the 161 studies in Crohn Disease with a site in Poland, this one is the 132nd largest by enrollment of the 152 interventional ones that give a count, is one of 10 that started in 2017, is one of 83 in phase 3, and was the 63rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

34 of the 161 studies in Crohn Disease with a site in Poland are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Crohn Disease with a site in Poland, or all of them as a file.
02

Study summary

An open label extension to the RHB-104-01 Study.

Read the detailed description

An Open Label Phase III Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Crohn's Disease,
  • moderate to severe
  • remission
  • Mycobacterium avium paratuberculosis
  • antibiotic
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed fully (ICF) provided as per this protocol.
  • Participation in RHB-104-01 for 26 weeks, and a Crohn's Disease Activity Index (CDAI) score of ≥ 150 at Visit Week 26.

OR

  • More than 26 weeks, with a CDAI ≥150 at Visit Week 26 and all subsequent visits, and subject is between Week 26 and 52 within 4 weeks (28 days) of site activation (e.g. Subject with CDAI = 249 at week 26 and who is at week 38 at the time of site's activation for RHB-104-04 has a 4-week window to be enrolled in the open label study via the Optional Screening Visit)
  • Current treatment with at least one of the following therapies which may be discontinued by the investigator as clinically indicated after 8 weeks of open label RHB-104 treatment:

    • Oral 5-acetyl salicylic acid (5-ASA) compounds
    • Azathioprine or 6-mercaptopurine (6-MP) or methotrexate
    • Infliximab or adalimumab OR Current treatment with therapy which must begin tapering after 4 weeks of treatment with open label RHB-104 (Refer to Appendix 13)
  • White blood cell count ≥ 3.5x109 at screening (RHB-104-01 Visit Week 26 visit or Optional Screening visit)
  • Subject agrees to use the following effective methods

    • diaphragm, cervical cap, contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository
    • IUD (intrauterine device) /IUS (intrauterine system)
    • progestogen injection (Depo-Provera®) throughout the study and for at least 6 weeks after last study drug administration, unless subject or partner of subject is or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation, or has had a vasectomy. Post-menopausal is defined as having experienced 12 consecutive months without menstruation.

In regions where local regulatory contraceptive requirements differ, the ICF (Informed Consent Form) will reflect local policies.

Exclusion criteria

Exclusion Criteria:

  1. Positive stool results for C. difficile.
  2. Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or optometrist.
  3. Treatment with any medication that causes or Torsades de Pointes, including but not limited to: amiodarone, amitriptyline, astemizole, cisapride, citalopram dose greater than 20 mg/day, dihydroergotamine, disopyramide, dofetilide, dronedarone, ergotamine, ibutilide, ondansetron or other 5-HT3 (5-hydroxytryptamine three) receptor antagonists, pimozide, procainamide, quinidine, quinine, quinolones, ranolazine, risperidone, sotalol, terfenadine and tolterodine. QT prolonging drugs may be referenced at the CredibleMeds® web site: https://crediblemeds.org/index.php/drugsearch/
  4. Treatment with the following interactive medications: alfentanyl, alprazolam, amlodipine, anti-retroviral agents, apixaban, aprepitant, aripiprazole, atorvastatin, boceprevir, buspirone, carbamazepine, carvedilol, colchicine, cyclosporine, digoxin, diltiazem, estrogens, felodipine, fluconazole, fluvoxamine, grapefruit juice, haloperidol, ketoconazole, lovastatin, lurasidone, metoprolol, nefazodone, nifedipine, nisoldipine, nitrendipine, propranol, roflumilast, simvastatin, St. John's wort, and voriconazole.
  5. Any evidence of any newly diagnosed significant hematological, hepatic, renal, cardiac, pulmonary, metabolic, neurological, psychiatric or other disease (e.g. porphyria) that might interfere with subject's ability to safely enter and or complete the study requirements.
  6. Females who have a positive pregnancy test or are lactating.
  7. Refusal to sign the study form.
  8. Inability to be able to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.
  9. abnormalities of hematology or biochemistry as confirmed by repeat testing based on investigator's discretion, including but not limited to, elevations greater than 2 times the of (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) or less than 60 ml/min at screening via estimated Cockcroft-Gault formula:

    Creatinine Clearance = [140 - age in years] * weight (kg) / 72 * Serum Creatinine (mg/dl) [multiply estimated rate by 0.85 for women], using actual body weight.

  10. QTcF (shortening of the QT interval in the heart rate) >450ms in males and QTcF>460ms in females, bundle branch block, or major ST or T wave abnormalities that make the assessment of the QT impossible.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    RHB-104 - patients on ACTIVE therapy in RHB-104-01 study

    Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study

    Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

  • Experimental
    RHB-104 - patients on PLACEBO therapy in RHB-104-01 study

    Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.

    Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

Interventions

  • DrugRHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    Drug page: Clarithromycin

    For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks

    Also known as: RHB-104

06

What researchers measure

Primary outcomes

  1. Number of Patients in Remission at Week 16

    The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points. Lower CDAI scores indicate a better outcome.

    Time frame: Week 16

Secondary outcomes

  1. Response at Week 16

    Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome.

    Time frame: Week 16

  2. The Number of Weeks for Patients to Achieve Remission

    \[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1\] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment.

    Time frame: Baseline through week 52

  3. Number of Weeks the Patients Are in Remission

    Duration of remission is defined as the number of weeks the subject is in remission (CDAI score \< 150). It is calculated as the first date following remission at which CDAI is ≥150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.

    Time frame: Baseline through week 52

  4. Number of Weeks to Achieve Response

    \[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1\] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.

    Time frame: Baseline through week 52

  5. Number of Weeks the Patients Are in Response.

    Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of ≥ 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is \<100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.

    Time frame: Baseline through week 52

  6. Durable Remission Week 16 Through Week 52

    When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52.

    Time frame: Week 16 through week 52

Other outcomes

  1. Increase in Milliseconds (ms) QT Wave

    The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report).

    Time frame: week 52

07

Results

Posted Feb 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneRHB-104 From RHB-104RHB-104 From Placebo
Started1638
Completed921
Not completed717

Outcome measures

PrimaryNumber of Patients in Remission at Week 16

The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points. Lower CDAI scores indicate a better outcome.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Patients in Remission at Week 16
ParticipantsRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Number of Patients in Remission at Week 16314
SecondaryResponse at Week 16

Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Response at Week 16
ParticipantsRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Response at Week 16414
SecondaryThe Number of Weeks for Patients to Achieve Remission

\[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1\] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment.

Time frame:
Baseline through week 52
Reported as:
Median · weeks
The Number of Weeks for Patients to Achieve Remission
weeksRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
The Number of Weeks for Patients to Achieve RemissionNA (NA to NA)25.1 (16.00 to 56.00)
Statistical analysis
  • RHB-104 From ACTIVE Arm of RHB-104-01 vs RHB-104 From PLACEBO Arm of RHB-104-01 · Log Rank · p = 0.2112
SecondaryNumber of Weeks the Patients Are in Remission

Duration of remission is defined as the number of weeks the subject is in remission (CDAI score \< 150). It is calculated as the first date following remission at which CDAI is ≥150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.

Time frame:
Baseline through week 52
Reported as:
Median · weeks
Number of Weeks the Patients Are in Remission
weeksRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Number of Weeks the Patients Are in Remission11.7 (NA to NA)45.0 (23.00 to NA)
Statistical analysis
  • RHB-104 From ACTIVE Arm of RHB-104-01 vs RHB-104 From PLACEBO Arm of RHB-104-01 · Log Rank · p = 0.0356
SecondaryNumber of Weeks to Achieve Response

\[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1\] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.

Time frame:
Baseline through week 52
Reported as:
Median · Weeks
Number of Weeks to Achieve Response
WeeksRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Number of Weeks to Achieve ResponseNA (16.14 to NA)26.1 (9.14 to 56.00)
Statistical analysis
  • RHB-104 From ACTIVE Arm of RHB-104-01 vs RHB-104 From PLACEBO Arm of RHB-104-01 · Log Rank · p = 0.0514
SecondaryNumber of Weeks the Patients Are in Response.

Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of ≥ 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is \<100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.

Time frame:
Baseline through week 52
Reported as:
Median · Weeks
Number of Weeks the Patients Are in Response.
WeeksRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Number of Weeks the Patients Are in Response.29.4 (10.86 to NA)45.0 (26.14 to NA)
Statistical analysis
  • RHB-104 From ACTIVE Arm of RHB-104-01 vs RHB-104 From PLACEBO Arm of RHB-104-01 · Log Rank · p = 0.1259
SecondaryDurable Remission Week 16 Through Week 52

When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52.

Time frame:
Week 16 through week 52
Reported as:
Count of participants · Participants
Durable Remission Week 16 Through Week 52
ParticipantsRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Durable Remission Week 16 Through Week 5217
Statistical analysis
  • RHB-104 From ACTIVE Arm of RHB-104-01 vs RHB-104 From PLACEBO Arm of RHB-104-01 · Fisher Exact · p = 0.4114
Other pre-specifiedIncrease in Milliseconds (ms) QT Wave

The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report).

Time frame:
week 52
Reported as:
Least squares mean · ms
Increase in Milliseconds (ms) QT Wave
msRHB-104 From ACTIVE Arm of RHB-104-01RHB-104 From PLACEBO Arm of RHB-104-01
Increase in Milliseconds (ms) QT Wave23.9 (17.77 to 30.02)27.6 (23.66 to 31.63)

Adverse events

Collected over Baseline through 30 days after last dose of study drug, or up to 13 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RHB-104 From RHB-1040/16 (0%)1/16 (6.3%)14/16 (87.5%)
RHB-104 From Placebo0/38 (0%)4/38 (10.5%)24/38 (63.2%)
Most frequent serious events
Most frequent serious events
EventRHB-104 From RHB-104RHB-104 From Placebo
Crohn's diseaseGastrointestinal disorders1/160/38
Abdominal PainGastrointestinal disorders0/161/38
DiverticulitisInfections and infestations0/161/38
Procedural painInjury, poisoning and procedural complications0/161/38
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/161/38
Peripheral Arterial Occlusive DiseaseVascular disorders0/161/38
Most frequent other events
Showing 10 of 44
Most frequent other events
EventRHB-104 From RHB-104RHB-104 From Placebo
ChromaturiaRenal and urinary disorders2/169/38
Crohn's DiseaseGastrointestinal disorders1/166/38
NauseaGastrointestinal disorders2/164/38
Abdominal painGastrointestinal disorders2/163/38
Dry mouthGastrointestinal disorders2/161/38
Weight decreasedInvestigations2/161/38
Weight increasedInvestigations2/161/38
Urinary tract infectionInfections and infestations2/162/38
ArthralgiaMusculoskeletal and connective tissue disorders2/163/38
VomitingGastrointestinal disorders1/163/38

Baseline characteristics

Total Study

Age, Continuous
Age, Continuous(years)RHB-104
RHB-104 from RHB-10448.6 ± 9.92
RHB-104 from placebo40.0 ± 13.24
Sex: Female, Male
Sex: Female, Male(Participants)RHB-104
RHB-104 from RHB-104 — Female6
RHB-104 from RHB-104 — Male10
RHB-104 from placebo — Female18
RHB-104 from placebo — Male20
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RHB-104
RHB-104 from RHB-104 — American Indian or Alaska Native0
RHB-104 from RHB-104 — Asian0
RHB-104 from RHB-104 — Native Hawaiian or Other Pacific Islander0
RHB-104 from RHB-104 — Black or African American1
RHB-104 from RHB-104 — White15
RHB-104 from RHB-104 — More than one race0
RHB-104 from RHB-104 — Unknown or Not Reported0
RHB-104 from placebo — American Indian or Alaska Native1
RHB-104 from placebo — Asian0
RHB-104 from placebo — Native Hawaiian or Other Pacific Islander0
RHB-104 from placebo — Black or African American1
RHB-104 from placebo — White36
RHB-104 from placebo — More than one race0
RHB-104 from placebo — Unknown or Not Reported0
Baseline Crohn's Disease Activity Index (CDAI) score
Baseline Crohn's Disease Activity Index (CDAI) score(units on a scale)RHB-104
RHB-104 from RHB-104295.42 ± 82.865
RHB-104 from placebo271.67 ± 58.379
08

Study locations

24 sites
  • Digestive Care Associates, Inc., 1000 Laurel Street
    San Carlos, California 94070, United States
  • Gastrointestinal Specialists of Georgia PC 711 Canton Rd. #300
    Marietta, Georgia 30060, United States
  • Cotton-O'Neil Clinical Research Center, 720 SW Lane St.
    Topeka, Kansas 66606, United States
  • Chevy Chase Clinical Research, 5550 Friendship Blvd.
    Chevy Chase, Maryland 20815, United States
  • Commonwealth Clinical Studies, 189 Quincy St.
    Brockton, Massachusetts 02302-2926, United States
  • ClinSearch 6035 Shallowford Road Suite 109
    Chattanooga, Tennessee 37421, United States
  • Discovery Clinical Services Ltd., 601 A Discovery St.
    Victoria, British Columbia V8T 5G4, Canada
  • Gastroenterologie s.r.o. Manesova 646
    Hradec Kralove, 500 02, Czechia
  • Hepato-Gastroenterologie HK, s.r.o., Hradecka poliklinika III Trida Edvarda Benese 1549/34
    Hradec Králové, 500 12, Czechia
  • Ha'Emek Medical Center, Institute of Gastroenterology and Liver diseases, 21 Yitshak Rabin Boulevard
    Afula, 1834111, Israel
  • Gastroenterology Institute, Division of Medicine, Hadassah - Hebrew University Medical Center POB 12000
    Jerusalem, 91120, Israel
  • Meir Medial Center, 59 Tchemacovsky St.
    Kfar-Saba, 44281, Israel
  • Christchurch Hospital, 2 Riccarton Rd.
    Christchurch, Canterbury 80011, New Zealand
  • Waikato Hospital, Department of Gastroenterology, Level B1, Menzies Building, Pembroke Street
    Hamilton, Waikato 3240, New Zealand
  • NZOZ Specjalistyczne Centrum Gastrologii GASTROMED, Wiejska 81
    Białystok, 15-351, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej MSW W Gdańsku Oddział Gastroenterologiczny, Ul. Kartuska 4/6
    Gdansk, 80-104, Poland
  • UNICARDIA Specjalistyczne Centrum Leczenia Chorob Serca i Naczyn & UNIMEDICA. Specjalistyczne Centrum Medyczne Sp. z o.o., Kluczborska 15
    Kraków, 31-271, Poland
  • Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny, Zolnierska 18
    Olsztyn, 10-561, Poland
  • EuroMedis sp. z.o.o., Al. Powstancow Wielkopolskich 33a
    Szczecin, 70-111, Poland
  • Centralny Szpital Kliniczny MSW w Warszawie. Klinika Chorob Wewnetrznych i Gastroenterologii, Woloska 137,
    Warsaw, 02-507, Poland
  • ARS MEDICA s.c., Powstancow Slaskich 56A/2
    Wroclaw, 53-333, Poland
  • Clinical Department of Gastroenterology and Hepatology Clinic for Internal Diseases Clinical Hospital Center Zvezdara Dimitrija Tucovica 161
    Belgrade, 11000, Serbia
  • Department of Gastroenterology and Hepatology, Clinical Hospital Center Zemun, Vukova 9
    Belgrade, 11080, Serbia
  • Center for Gastroenterohepatology, Clinic for Internal Medicine, Clinical Center Kragujevac, Zmaj Jovina 30
    Kragujevac, 34000, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Nov 2018, 19 months.

Results were first posted in Feb 2021, 2 years 3 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 19 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2016
First posted
Jan 4, 2017
StartActual
Mar 18, 2017
Primary completionActual
Nov 13, 2018
CompletionActual
Aug 19, 2019
Results first posted
Feb 24, 2021
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03009396
Lead sponsor
RedHill Biopharma Limited
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Mar 18, 2017
Primary completion
Nov 13, 2018
Completion
Aug 19, 2019
Results posted
Feb 24, 2021
Last update
Feb 24, 2021

Study contacts

Ira N Kalfus, MD
study director · RedHill Biopharma Limited
David Y Graham, MD
principal investigator · Department of Medicine / Gastroenterology, Baylor College of Medicine, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clarithromycin

Start the discussion